SERUM TUMOR NECROSIS FACTOR-&agr; IN GUILLAIN-BARRé SYNDROME AND ITS RELATION TO PLASMA EXCHANGE

BACKGROUND–To correlate the serum tumor necrosis factor-&agr; (TNF&agr;) concentrations before, during and following plasma exchange in patients with Guillain-Barré syndrome (GBS). In this prospective study, 21 GBS patients were selected. Patients in clinical stages III to V were subjected to plasma exchange. The control group included equal numbers of age-matched patients with other neurological diseases and healthy voluntary blood donors. A sandwich ELISA method was applied to estimate serum TNF&agr; concentrations in test and control groups. REVIEW SUMMARY–Twelve GBS patients had elevated serum TNF&agr; levels that ranged between 74 and 182 pg/mL. All 12 GBS patients showed a steady decrease in the TNF&agr; concentration following plasma exchange and also showed a positive correlation with neurological recovery. CONCLUSIONS–We conclude that serum TNF&agr; concentrations are elevated in 57.1% of GBS patients and TNF&agr; level decreases following plasma exchange.

[1]  M. Swash,et al.  IV immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome , 1999, Neurology.

[2]  D. Aderka.  The potential biological and clinical significance of the soluble tumor necrosis factor receptors. , 1996, Cytokine & growth factor reviews.

[3]  H. Hartung,et al.  Inflammatory infiltrates in sural nerve biopsies in Guillain‐Barré syndrome and chronic inflammatory demyelinating neuropathy , 1996, Muscle & nerve.

[4]  A. Exley,et al.  Tumour necrosis factor-alpha and other cytokines in Guillain-Barré syndrome. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[5]  E. Thompson,et al.  Elevated serum levels of tumor necrosis factor‐α in Guillain‐Barré syndrome , 1993 .

[6]  W. Kisiel,et al.  Tumor necrosis factor-induced endothelial tissue factor is associated with subendothelial matrix vesicles but is not expressed on the apical surface , 1992 .

[7]  E. Thompson,et al.  Blood-Brain Barrier Damage in Patients with Bacterial Meningitis: Association with Tumor Necrosis Factor-α but not Interleukin-Iβ , 1992 .

[8]  R. Hughes,et al.  Sural nerve biopsies in Guillain‐Barre syndrome: Axonal degeneration and macrophage‐associated demyelination and absence of cytomegalovirus genome , 1992, Muscle & nerve.

[9]  D. Willenborg,et al.  Direct injection of cytokines into the spinal cord causes autoimmune encephalomyelitis-like inflammation , 1990, Journal of the Neurological Sciences.

[10]  R. Hughes,et al.  T lymphocyte activation antigens in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy , 1989, Journal of Neuroimmunology.

[11]  A. Cerami,et al.  Detection of circulating tumor necrosis factor after endotoxin administration. , 1988, The New England journal of medicine.

[12]  K. Selmaj,et al.  Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro , 1988, Annals of neurology.

[13]  K. Tracey,et al.  Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation , 1988, The Journal of experimental medicine.

[14]  R. Hughes,et al.  CONTROLLED TRIAL OF PREDNISOLONE IN ACUTE POLYNEUROPATHY , 1978, The Lancet.

[15]  V. Dubowitz,et al.  Identification of regenerated dystrophic minced muscle transplanted in normal mice , 1975, Journal of the Neurological Sciences.

[16]  R. Adams,et al.  The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. , 1969, Medicine.

[17]  Hughes Ra.  Immunological mechanisms of demyelination. , 1992 .

[18]  G. Stoll,et al.  Macrophage responses in inflammatory demyelinating neuropathies , 1990, Annals of neurology.

[19]  H. Hartung,et al.  T‐Cell and macrophage activation in experimental autoimmune neuritis and Guillain‐Barré syndrome , 1990, Annals of neurology.

[20]  D. Cornblath,et al.  Assessment of current diagnostic criteria for Guillain‐Barré syndrome , 1990, Annals of neurology.